Prognostic Models for Predicting Overall Survival in Patients with Primary Gastric Cancer: A Systematic Review

Abstract

Background. This study was designed to review the methodology and reporting of gastric cancer prognostic models and identify potential problems in model development. Methods. This systematic review was conducted following the CHARMS checklist. MEDLINE and EMBASE were searched. Information on patient characteristics, methodological details, and models’ performance was extracted. Descriptive statistics was used to summarize the methodological and reporting quality. Results. In total, 101 model developments and 32 external validations were included. The median (range) of training sample size, number of death, and number of final predictors were 360 (29 to 15320), 193 (14 to 9560), and 5 (2 to 53), respectively. Ninety-one models were developed from routine clinical data. Statistical assumptions were reported to be checked in only nine models. Most model developments (94/101) used complete-case analysis. Discrimination and calibration were not reported in 33 and 55 models, respectively. The majority of models (81/101) have never been externally validated. None of the models have been evaluated regarding clinical impact. Conclusions. Many prognostic models have been developed, but their usefulness in clinical practice remains uncertain due to methodological shortcomings, insufficient reporting, and lack of external validation and impact studies. Impact. Future research should improve methodological and reporting quality and emphasize more on external validation and impact assessment.

<p>LINC01272 Promotes Migration and Invasion of Gastric Cancer Cells via EMT</p>

“…1,2 The prognosis of several patients diagnosed with GC is poor, especially that of patients with advanced GC. 22,23 Identification of specific early diagnostic markers is key to GC diagnosis. LncRNAs have been shown to be closely associated with lymph node metastasis, distant metastasis, and tumor differentiation in GC.…”

Gastric cancer in East Azerbaijan, Iran: Five-year survival analysis of population-based cancer registry results

“…However, in cases with advanced stage, the prognosis is poor. Recently, the average 5-year survival rate was 31% in the United States, 19% in the United Kingdom, and 26% in Europe 16,17 . Gastric cancer is ranked as the leading cause of cancer-related deaths in Iran, accounting for 16.1% of cancer-related deaths.…”

Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis

“…Cancers of the upper gastrointestinal (GI) tract including gastric, esophageal, and gastroesophageal junction (GEJ) cancer are among the most common and deadly malignant diseases worldwide [1]. Survival in these patients is generally poor and reliable prognostic markers are scarce, especially in European cohorts [2]. Given that clinical outcomes have been found to vary substantially even within the same stage groups, new prognostic tools are needed.…”